WAYNE, Pa. and MISGAV, Israel, April 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) (LSE:MEDU) (LSE:MEDG), the developer of BioPump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 7.7 million (approximately USD 2.2 million), from the Office of the Chief Scientist (OCS) at the Ministry of Economy of Israel.
The grant will be used to cover Research & Development (R&D) expenses for the 12-month period from December 2013 through November 2014 to support further research and clinical development of the Company's proprietary, tissue-based BioPump platform technology with respect to the treatment of new rare and orphan diseases and anemia.
The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company's business including financial position, R&D capabilities and management experience.
Under the terms of the OCS grant, MMI will repay the grant in full, plus interest, through royalties on revenue received from commercializing the developed technology. The payment of royalties is contingent on such revenues and, in the absence of such revenues; no royalty payments to the OCS are required.
"We are delighted and honored to once again have been selected to receive this non-dilutive funding from the Israeli OCS and appreciate the continued support. These grants have been instrumental in furthering the development of our BioPump technology and support us in advancing our clinical trials in the U.S. and Israel," stated Garry A. Neil, Global Head of R&D for Medgenics.
Medgenics is developing and commercializing BioPump™, a proprietary platform for the sustained production and delivery of therapeutic proteins using ex-vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
CONTACT: Medgenics, Inc. John Leaman firstname.lastname@example.org Stern Investor Relations Beth DelGiacco 212-362-1200 Beth@sternir.com Abchurch Communications Harriet Rae / Joanne Shears/Jamie Hooper +44 207 398 7719 email@example.com Oriel Securities (NOMAD & Broker) Jonathan Senior / Giles Balleny +44 207 710 7617Source:Medgenics, Inc.